Journal article

Immunogenicity, transplacental transfer of pertussis antibodies and safety following pertussis immunization during pregnancy: Evidence from a randomized, placebo-controlled trial

Kirsten P Perrett, Scott A Halperin, Terry Nolan, Cristina Martinez Pancorbo, Bruce Tapiero, Federico Martinon-Torres, Zbynek Stranak, Miia Virta, Otto G Vanderkooi, Pavel Kosina, Maria Begona Encinas Pardilla, Ignacio Cristobal Garcia, Gian Vincenzo Zuccotti, Lusine Kostanyan, Nadia Meyer, Maria Angeles Ceregido, Brigitte Cheuvart, Sherine O Kuriyakose, Manuel Marcos Fernandez, Miguel Angel Rodriguez Zambrano Show all

Vaccine | ELSEVIER SCI LTD | Published : 2020


BACKGROUND: Pertussis immunization during pregnancy is recommended in many countries. Data from large randomized controlled trials are needed to assess the immunogenicity, reactogenicity and safety of this approach. METHODS: This phase IV, observer-blind, randomized, placebo-controlled, multicenter trial assessed immunogenicity, transplacental transfer of maternal pertussis antibodies, reactogenicity and safety of a reduced-antigen-content diphtheria-tetanus-three-component acellular pertussis vaccine (Tdap) during pregnancy. Women received Tdap or placebo at 27-36 weeks' gestation with crossover ≤ 72-hour-postpartum immunization. Immune responses were assessed before the pregnancy dose and ..

View full abstract